Non-Insulin Treatments for Diabetes

被引：3
作者：
Angueira, Eugenio [1 ,2 ,3 ]
机构：
[1] TRUE Hlth Wellness, Yardley, PA USA
[2] Florida Int Univ, Miami, FL 33199 USA
[3] Novo Nordisk Inc, Princeton, NJ USA
来源：
AMERICAN JOURNAL OF THERAPEUTICS | 2013年 / 20卷 / 04期
关键词：
GLP-1; incretin; exenatide; liraglutide; pramlintide; GLUCAGON-LIKE PEPTIDE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; BETA-CELL FUNCTION; GLYCEMIC CONTROL; EXENATIDE EXENDIN-4; DOUBLE-BLIND; TREATED PATIENTS; WEIGHT CONTROL; AMYLIN ANALOG; OPEN-LABEL;
D O I：
10.1097/MJT.0b013e318235f2cb
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aimed to review newer therapeutic agents for the treatment of diabetes that are related to hormones responsible for glucose metabolism other than insulin. Data from several new therapeutic agents were reviewed to provide an overview of the efficacy and tolerability of these agents. With a greater understanding of the physiology of glucose homeostasis and the pathophysiology of diabetes, new therapeutic agents have been developed to address other hormonal deficiencies/defects that are seen in the disease. These new agents fall under the categories of incretin-related therapies, such as glucagon-like peptide-1 mimetics, glucagon-like peptide-1 analogs, dipeptidyl peptidase-4 inhibitors, and amylin analogs. A1c reductions with these agents range from 0.4% to 1.6% (depending on each agent), with added benefits such as weight neutrality/loss and low risk for hypoglycemia.
引用
收藏
页码：376 / 383
页数：8
相关论文
共 53 条
  • [31] Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
    Knudsen, Lotte Bjerre
    Madsen, Lars Wichmann
    Andersen, Soren
    Almholt, Kasper
    de Boer, Anne S.
    Drucker, Daniel J.
    Gotfredsen, Carsten
    Egerod, Frederikke Lihme
    Hegelund, Anne Charlotte
    Jacobsen, Helene
    Jacobsen, Soren Dyring
    Moses, Alan C.
    Molck, Anne-Marie
    Nielsen, Henriette S.
    Nowak, Jette
    Solberg, Helene
    Thi, Tu D. L.
    Zdravkovic, Milan
    [J]. ENDOCRINOLOGY, 2010, 151 (04) : 1473 - 1486
  • [32] AMYLIN CONCENTRATIONS AND GLUCOSE CONTROL
    KODA, JE
    FINEMAN, M
    RINK, TJ
    DAILEY, GE
    MUCHMORE, DB
    LINARELLI, LG
    [J]. LANCET, 1992, 339 (8802) : 1179 - 1180
  • [33] Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
    Kolterman, OG
    Buse, JB
    Fineman, MS
    Gaines, E
    Heintz, S
    Bicsak, TA
    Taylor, K
    Kim, D
    Aisporna, M
    Wang, Y
    Baron, AD
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (07) : 3082 - 3089
  • [34] DECREASE OF STIMULATED AMYLIN RELEASE PRECEDES IMPAIRMENT OF INSULIN-SECRETION IN TYPE-II DIABETES
    LUDVIK, B
    LELL, B
    HARTTER, E
    SCHNACK, C
    PRAGER, R
    [J]. DIABETES, 1991, 40 (12) : 1615 - 1619
  • [35] Effect of pramlintide on A1C and body weight in insulin-treated African Americans and hispanics with type 2 diabetes:: A pooled post hoc analysis
    Maggs, D
    Shen, L
    Strobel, S
    Brown, D
    Kolterman, O
    Weyer, C
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (12): : 1638 - 1642
  • [36] Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
    Marre, M.
    Shaw, J.
    Braendle, M.
    Bebakar, W. M. W.
    Kamaruddin, N. A.
    Strand, J.
    Zdravkovic, M.
    Le Thi, T. D.
    Colagiuri, S.
    [J]. DIABETIC MEDICINE, 2009, 26 (03) : 268 - 278
  • [37] Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Miller, Shannon A.
    St. Onge, Erin L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2006, 40 (7-8) : 1336 - 1343
  • [38] Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
    Nauck, M. A.
    Ellis, G. C.
    Fleck, P. R.
    Wilson, C. A.
    Mekki, Q.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (01) : 46 - 55
  • [39] Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
    Nauck, Michael
    Frid, Anders
    Hermansen, Kjeld
    Shah, Nalini S.
    Tankova, Tsvetalina
    Mitha, Ismail H.
    Zdravkovic, Milan
    During, Maria
    Matthews, David R.
    [J]. DIABETES CARE, 2009, 32 (01) : 84 - 90
  • [40] Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes A retrospective cohort study
    Noel, Rebecca A.
    Braun, Daniel K.
    Patterson, Ruth E.
    Bloomgren, Gary L.
    [J]. DIABETES CARE, 2009, 32 (05) : 834 - 838
123456